Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2024 18:33 ET | Source: Research and Markets

Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032

Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
July 24, 2023 05:08 ET | Source: Research and Markets

Global Prostate Cancer Drugs Market Shows Robust Growth, Projected to Reach $23.50 Billion in 2027

Dublin, July 24, 2023 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer drugs market...
February 23, 2023 05:23 ET | Source: Research and Markets

Head and Neck Cancer Therapeutics Global Market 2022: Sector to Reach $3.5 Billion by 2030 with APAC Being the Fastest Growing Region

Dublin, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The "Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By...
September 16, 2022 08:23 ET | Source: Research and Markets

Global Head and Neck Cancer Therapeutics Market Report 2022: Advances in Biochemistry and Genomics Fuels Sector

Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a...
September 12, 2022 07:30 ET | Source: Theratechnologies

L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale

Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
September 12, 2022 07:30 ET | Source: Theratechnologies

Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth

Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
August 24, 2022 05:08 ET | Source: Research and Markets

Global Head & Neck Cancer Drugs Market (2022 to 2027) - Featuring AbbVie, Amgen and Gilead Sciences Among Others

Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Head & Neck Cancer Drugs Market (2022-2027) by Drug Class, Product, End User, Geography, Competitive Analysis and the Impact of Covid-19...
July 07, 2022 01:30 ET | Source: Spexis AG

Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated...
January 05, 2022 06:33 ET | Source: Research and Markets

Global Head & Neck Cancer Drugs Market Research Report (2021 to 2026) - by Drug Class, Product, End-user and Region

Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
December 31, 2021 05:43 ET | Source: Research and Markets

Investigation Report on China's CNY1.112 Billion Docetaxel Market 2021-2025

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Docetaxel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to the market...